Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder

2018 ◽  
Vol 385 ◽  
pp. 64-68 ◽  
Author(s):  
Hiroki Masuda ◽  
Masahiro Mori ◽  
Akiyuki Uzawa ◽  
Tomohiko Uchida ◽  
Ryohei Ohtani ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Interleukin 6 ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Impact Scale ◽  
Fatigue Impact Scale

scholarly journals Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology

2020 ◽  
Vol 7 (5) ◽  
pp. e841 ◽  
Author(s):  
Kazuo Fujihara ◽  
Jeffrey L. Bennett ◽  
Jerome de Seze ◽  
Masayuki Haramura ◽  
Ingo Kleiter ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Interleukin 6 ◽  
Case Series ◽  
Autoimmune Disorder ◽  
Multiple Roles ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Neurologic Disability ◽  
Recent Phase

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder that preferentially affects the spinal cord and optic nerve. Most patients with NMOSD experience severe relapses that lead to permanent neurologic disability; therefore, limiting frequency and severity of these attacks is the primary goal of disease management. Currently, patients are treated with immunosuppressants. Interleukin-6 (IL-6) is a pleiotropic cytokine that is significantly elevated in the serum and the CSF of patients with NMOSD. IL-6 may have multiple roles in NMOSD pathophysiology by promoting plasmablast survival, stimulating the production of antibodies against aquaporin-4, disrupting blood-brain barrier integrity and functionality, and enhancing proinflammatory T-lymphocyte differentiation and activation. Case series have shown decreased relapse rates following IL-6 receptor (IL-6R) blockade in patients with NMOSD, and 2 recent phase 3 randomized controlled trials confirmed that IL-6R inhibition reduces the risk of relapses in NMOSD. As such, inhibition of IL-6 activity represents a promising emerging therapy for the management of NMOSD manifestations. In this review, we summarize the role of IL-6 in the context of NMOSD.

scholarly journals Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

2015 ◽  
Vol 72 (7) ◽  
pp. 756 ◽  
Author(s):  
Marius Ringelstein ◽  
Ilya Ayzenberg ◽  
Jens Harmel ◽  
Ann-Sophie Lauenstein ◽  
Eckart Lensch ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Interleukin 6 ◽  
Spectrum Disorder ◽  
Term Therapy ◽  
Receptor Blockade ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Highly Active ◽  
Interleukin 6 Receptor ◽  
Long Term Therapy

scholarly journals Neuromyelitis optica spectrum disorder with deafness and an extensive brainstem lesion

Heliyon ◽  
2021 ◽  
Vol 7 (1) ◽  
pp. e06106
Author(s):  
Asako Onda ◽  
Mikihiro Yamazaki ◽  
Takashi Shimoyama ◽  
Hiroshi Yaguchi
Keyword(s):  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Brainstem Lesion

Sleep disorders as a possible predisposing attack factor in neuromyelitis optica spectrum disorder (NMOSD): A case-control study

2021 ◽  
Vol 204 ◽  
pp. 106606
Author(s):  
Samaneh Haji Molla Rabi ◽  
Shaghayegh Shahmirzaei ◽  
Mohammad Ali Sahraian ◽  
Razieh Sadat Kazemi Mozdabadi ◽  
Hossein Rezaei Aliabadi ◽  
...  
Keyword(s):  
Sleep Disorders ◽  
Neuromyelitis Optica ◽  
Case Control Study ◽  
Case Control ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Control Study

scholarly journals The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhila Maghbooli ◽  
Abdorreza Naser Moghadasi ◽  
Nasim Rezaeimanesh ◽  
Abolfazl Omidifar ◽  
Tarlan Varzandi ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Neuromyelitis Optica ◽  
Serum Levels ◽  
Spectrum Disorder ◽  
Control Group ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Downstream Signaling ◽  
Reduce Insulin Sensitivity ◽  
Circulating Levels

Abstract Background Neuromyelitis optica spectrum disorder (NMOSD) is associated with inflammatory mediators that may also trigger downstream signaling pathways leading to reduce insulin sensitivity. Methods We aimed to determine the risk association of hyperinsulinemia in NMOSD patients with seropositive AQP4-IgG and the serum levels of interleukin (IL)-6 and IL-17A compared with the control group. Serum levels of metabolic (Insulin, Fasting Blood Sugar (FBS), lipid profile) and inflammatory (IL-6 and IL-17) markers were assessed in 56 NMOSD patients and 100 controls. Results Hyperinsulinemia was more prevalent in NMOSD patients independent of age, sex and body mass index (BMI) (48.2% vs. 26%, p = 0.005) compared to control group. After adjusting age, sex and BMI, there was significant association between lower insulin sensitivity (IS) and NMOSD risk (95% CI: Beta = 0.73, 0.62 to 0.86, p = 0.0001). Circulating levels of IL-6 and IL-17 were higher in NMOSD patients, and only IL-6 had an effect modifier for the association between lower insulin sensitivity and NMOSD risk. Conclusions Our data suggests that inflammatory pathogenesis of NMOSD leads to hyperinsulinemia and increases the risk of insulin resistance.

Sign in / Sign up

Export Citation Format

Share Document